IN VIVO EVALUATION OF TAZAROTENE SOLID LIPID NANOPARTICLES GEL FOR TOPICAL DELIVERY
Abstract
The purpose of this research work was to develop and optimize the Solid Lipid Nanoparticles (SLNs) of Tazarotene for the effective topical delivery in the treatment of psoriasis. Tazarotene loaded SLNs were prepared by hot homogenization followed by the ultrasonication using Taguchi’s design and based on the results further investigation was made using central composite design. The lipid Dynasan-116, surfactant poloxomer-188 and co surfactant egg lecithin resulted in better percent drug loading and evaluated for particle size, zeta potential, TEM, drug entrapment efficiency, in vitro drug release and stability. All parameters were found to be in an acceptable range. In vitro drug release of optimized SLN formulation (F1) was found to be 98.12 ± 1.52%, whereas pure drug release was 42.12 after 60 min. The optimized formulation was incorporated into the gel. The release rate (flux) of tazarotene across the membrane and excised skin differs significantly. The accumulative amount of Tazarotene in skin from SLN based gel formulation and marketed gel were 41.12 ± 0.12 mg and 30.02 ± 0.04 mg respectively. This result supported our hypothesis made in skin permeation studies on rat skin. From histopathological studies the microscopic observations indicate that the optimized SLN formulation, SLN based gel formulation and marketed gel has no significant effect on the microscopic structure of the skin. The skin-irritation studies indicated that SLN based gel containing Tazarotene did not show any sign of skin irritation as compared to moderate erythema shown by marketed gel formulation (Tazret® gel) after 72 h of application. Thus, SLN based gel formulation demonstrated advantage over marketed formulation in improving the skin tolerability of Tazarotene indicating their potential in improving patient acceptance and topical delivery of Tazarotene.
Keywords:
Tazarotene, Psoriasis, Topical gel, Skin irritation studies, Histopathological studiesDOI
https://doi.org/10.25004/IJPSDR.2019.110107References
2. Dubey A, Kamath J. Nanostructured lipid carriers: a novel topical drug delivery system. Int J Pharm Tech Res. 2012; 4: 705-14.
3. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm. 1999; 184: 1-6.
4. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Delivery Rev. 2002; 54: 77-98.
5. Müller R, Radtke M, Wissing S. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery Rev. 2002; 54:131-55.
6. Muller-Goymann CC. Physiochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm. 2004; 58: 343–56.
7. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel. 2005; 107: 215–28.
8. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000; 50:161–77
9. Cavalli R, Caputo O, Carlotti ME. Sterilization and freeze drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm. 1997; 148:47–54
10. Emami J, Mohiti H, Hamishehkar H, Varshosaz J. Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci. 2015; 10(1): 17–33.
11. Roy A. Primer on the Taguchi Method. Van Nostrand Reinhold, New York, 1990.
12. Maia CS, Mehnert W, Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm. 2000; 196:165–7.
13. Bachhav YG, Patravale VB. Microemulsion based vaginal gel of fluconazole: Formulation, in vitro and in vivo evaluation. Int J Pharm. 2009; 365:175-179.
14. Laithy HM, Shaboury KMF. The development of cutinalipogels and gel microemulsion for topical administration of fluconazole. AAPS Pharm Sei Tech. 2002; 3: article 35.
15. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews 2012; 64:83–101.
16. 16. Patel MR, Patel RB, Parikh JR. Effect of formulation components on the in vitro permeation of microemulsion drug delivery system of fluconazole. AAPS Pharm Sci Tech. 2009; 10:917–923.
17. Biruss B, Valenta C. The advantage of polymer addition to a non-ionic oil in water microemulsion for the dermal delivery of progesterone. Int J Pharm. 2008; 349: 269 -273.
18. Patel RB, Patel MR, Bhatt KK, Patel BG. Risperidone loaded mucoadhesive microemulsion for intranasal delivery: formulation, development, physicochemical characterization and ex vivo evaluation. J Drug Del Sci Tech. 2013; 23: 261–267.
19. Draize J, Woodard G, Calvery H. Methods for the study of irritation and toxicity of substances topically applied to skin and mucous membranes. J Pharmacol Exp Ther. 1944; 82: 377–390.
Published
Abstract Display: 733 
PDF Downloads: 839 
